Literature DB >> 8304758

Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma.

P Heald1, S L Yan, R Edelson.   

Abstract

BACKGROUND AND
DESIGN: To accurately assess tumor burden in cutaneous T-cell lymphoma as well as to determine the number of residual normal circulating T cells, it is necessary to accurately distinguish malignant cells. Because cutaneous T-cell lymphoma cells regularly display many normal phenotypic markers of T cells (CD2+, CD3+, CD4+) these surface proteins have been of limited value. We have used a set of monoclonal antibodies with specificity for those T-cell receptor proteins containing variable regions on the beta chain to distinguish normal from malignant T cells in patients with cutaneous T-cell lymphoma.
RESULTS: The results revealed an unanticipated and profound expansion of the malignant cell populations (59% to 87% of blood T cells) in six patients with total T-cell counts in the normal or near normal range. By subtracting the percentages of malignant T cells, identified in this manner, from the total T-cell counts, we found that the residual normal T-cell compartments were small (0 to 0.155 x 10(9)/L) in four of the six patients. Sézary cell counts by peripheral blood smear analysis by routine light microscopy underestimated the number of malignant T cells. Markedly elevated CD4/CD8 ratios (10 to 90) occurred in all cases, reflecting expansion of the CD4+ malignant population and parallel reduction of the normal residual CD8+ subset.
CONCLUSIONS: Patients with erythrodermic cutaneous T-cell lymphoma often have markedly depressed levels of normal blood T cells, to the range seen in advanced acquired immunodeficiency syndrome, and absolute numbers of malignant cells substantially exceed those recognized with less sensitive techniques.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8304758

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

Review 1.  The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications.

Authors:  Ercole Mazzeo; Laura Rubino; Michela Buglione; Paolo Antognoni; Stefano Maria Magrini; Francesco Bertoni; Manuela Parmiggiani; Paola Barbieri; Filippo Bertoni
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-13

2.  Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.

Authors:  Juliet F Gibson; Jing Huang; Kristina J Liu; Kacie R Carlson; Francine Foss; Jaehyuk Choi; Richard Edelson; Jerry W Hussong; Ramsey Mohl; Sally Hill; Michael Girardi
Journal:  J Am Acad Dermatol       Date:  2016-02-10       Impact factor: 11.527

Review 3.  Aberrant responses of human lymphocytic neoplasms to cytokine regulation.

Authors:  P C Nowell; J S Moore
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

4.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Authors:  Elisabetta Capriotti; Eric C Vonderheid; Christopher J Thoburn; Mariusz A Wasik; David W Bahler; Allan D Hess
Journal:  Leuk Lymphoma       Date:  2008-06

Review 5.  Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.

Authors:  William E Damsky; Jaehyuk Choi
Journal:  Curr Treat Options Oncol       Date:  2016-07

6.  Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sézary patients.

Authors:  R J Capocasale; R J Lamb; E C Vonderheid; F E Fox; A H Rook; P C Nowell; J S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

7.  Eruptive squamous cell carcinomas in an erythrodermic patient.

Authors:  Alec J Ziemann; Michi M Shinohara; Melanie Kuechle
Journal:  JAAD Case Rep       Date:  2020-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.